Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 29 Dec 2018 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 29 Dec 2018 Planned primary completion date changed from 1 May 2019 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated